Earnings Call · Q2 FY2024·2024-08-11

Q2 24EPS -15.00%·Rev n/aQ1 24EPS +80.00%·Rev n/aQ4 23EPS -100.00%*·Rev n/aQ3 23EPS -28.57%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Mark Namaroff — Vice President, Investor Relations, ESG and Corporate Communications

Cheryl Blanchard — Chief Executive Officer

Steve Griffin — Chief Financial Officer

−1.0%1d on move date−3.4% vs SPY3d−3.4%5d−2.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access